Literature DB >> 6101790

Glucose metabolism and acetylcholine synthesis in relation to neuronal activity in Alzheimer's disease.

N R Sims, D M Bowen, C C Smith, R H Flack, A N Davison, J S Snowden, D Neary.   

Abstract

The metabolism of (U--14C) glucose and its incorporation into acetylcholine were determined in vitro in fresh cortical biopsy samples from patients with Alzheimer's disease and controls. Synthesis of 14C acetylcholine was significantly reduced (60% and 67% reduction under stimulated and resting conditions, respectively) without significant changes in the overall metabolism of glucose (as measured by 14CO2 production). Acetylcholine synthesis was directly related to the activity of choline acetyltransferase. The changes in cholinergic markers reflected the severity of psychological defects. Acetylcholine synthesis was not reduced in biopsy samples from patients suffering from presenile dementia with no histological evidence of Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6101790     DOI: 10.1016/s0140-6736(80)90884-3

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  37 in total

Review 1.  Brain fuel metabolism, aging, and Alzheimer's disease.

Authors:  Stephen Cunnane; Scott Nugent; Maggie Roy; Alexandre Courchesne-Loyer; Etienne Croteau; Sébastien Tremblay; Alex Castellano; Fabien Pifferi; Christian Bocti; Nancy Paquet; Hadi Begdouri; M'hamed Bentourkia; Eric Turcotte; Michèle Allard; Pascale Barberger-Gateau; Tamas Fulop; Stanley I Rapoport
Journal:  Nutrition       Date:  2010-10-29       Impact factor: 4.008

2.  Glucose metabolism as the site of the primary abnormality in early-onset dementia of Alzheimer type?

Authors:  S Hoyer; K Oesterreich; O Wagner
Journal:  J Neurol       Date:  1988-01       Impact factor: 4.849

3.  Long-term high-fat diet induces hippocampal microvascular insulin resistance and cognitive dysfunction.

Authors:  Zhuo Fu; Jing Wu; Tanseli Nesil; Ming D Li; Kevin W Aylor; Zhenqi Liu
Journal:  Am J Physiol Endocrinol Metab       Date:  2016-11-29       Impact factor: 4.310

Review 4.  Physostigmine for Alzheimer's disease.

Authors:  F Coelho; J Birks
Journal:  Cochrane Database Syst Rev       Date:  2001

5.  Physostigmine restores 3H-acetylcholine efflux from Alzheimer brain slices to normal level.

Authors:  L Nilsson; A Nordberg; J Hardy; P Wester; B Winblad
Journal:  J Neural Transm       Date:  1986       Impact factor: 3.575

6.  Absorption, metabolism, and disposition of [14C]SDZ ENA 713, an acetylcholinesterase inhibitor, in minipigs following oral, intravenous, and dermal administration.

Authors:  F L Tse; R Laplanche
Journal:  Pharm Res       Date:  1998-10       Impact factor: 4.200

Review 7.  Microglia-Mediated Inflammation and Neurodegenerative Disease.

Authors:  Ling Xu; Dan He; Ying Bai
Journal:  Mol Neurobiol       Date:  2015-12-10       Impact factor: 5.590

8.  The noradrenergic system in Alzheimer and multi-infarct dementias.

Authors:  D M Mann; P O Yates; J Hawkes
Journal:  J Neurol Neurosurg Psychiatry       Date:  1982-02       Impact factor: 10.154

9.  Alzheimer's disease is type 3 diabetes-evidence reviewed.

Authors:  Suzanne M de la Monte; Jack R Wands
Journal:  J Diabetes Sci Technol       Date:  2008-11

10.  Do tetrahydroaminoacridine (THA) and physostigmine restore acetylcholine release in Alzheimer brains via nicotinic receptors?

Authors:  L Nilsson; A Adem; J Hardy; B Winblad; A Nordberg
Journal:  J Neural Transm       Date:  1987       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.